Clinical Trials Browser

INDUSTRY × Blast Crisis × nilotinib × Clear all

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01368523 2016-11-16

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Phase 4 Completed

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00905593 2012-07-18

ENACT

Approved for marketing

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No longer available

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase